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Abstract—Hundreds of rare diseases are due to mutation on 
genes related to glycans synthesis, degradation or recognition. 
These glycan-related defects are well described in the literature 
but largely absent in ontologies and databases of chemical 
entities and phenotypes, limiting the application of computational 
methods and ontology-driven tools for characterization and 
discovery of glycan related diseases. We are curating articles and 
textbooks in glycobiology related to genetic diseases to inform the 
content and the structure of an ontology of Molecular Glyco-
Phenotypes (MGPO). MGPO will be applied toward use cases 
including disease diagnosis and disease gene candidate 
prioritization, using semantic similarity and pattern matching at 
the glycan level with glycomics data from patient of the 
Undiagnosed Diseases Network.  
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I. INTRODUCTION  
Rare diseases and disorders affect 25 million people in the 
United States, 30 million people Europe and 350 million 
worldwide [1]. 7,000 rare diseases and disorders have been 
identified and 80% of them are related to genetic defects [2]. 
More than 100 of these genetic defects are related to glycan 
biology, affecting glycan synthesis, degradation or recognition 
[3]. Glycans, also referred to as sugars, carbohydrates, 
monosaccharides or polysaccharides, can be found free or 
attached to macromolecules to form glycosphingolipids when 
attached to lipids, N or O-linked glycoproteins when attached 
to proteins or glycophosphatidylinositol (GPI)-anchored 
glycoproteins when glycoproteins are attached to GPI.  
Two broad categories define their biological roles:  
structural/modulatory function and intrinsic/extrinsic 
molecular recognition [4]. Glycan-related diseases can be 
observed by their glycan markers or glyco-phenotypes, 
defined as an abnormality related to glycan structure, level, 
activity, and processing. Many of these glycophenotypes can 
be detected in patients’ bodily fluids or cells (e.g. urine [5]).   
The Human Phenotype Ontology (HPO) is a structured 
clinical vocabulary that has been used for deep clinical 
phenotyping and allows the integration of data across sources 
and organisms. The ontology is the de facto standard for 
clinical phenotyping for rare disease diagnostics using 
phenotypic profile comparison [6]. Glycan-related defects and 
the molecules they affect are well described in the literature, 
but largely absent in ontologies such as the HPO, and from 
databases of chemical entities and phenotypes such as 
metabolomics databases like the ‘Metabolomics Workbench’ 
[7]. This limits our ability to apply computational methods and 
ontology-driven tools in the characterization and query of 
glycobiological diseases. Therefore, we are developing the 
Molecular Glyco-Phenotypes Ontology (MGPO).  
The MGPO aims to address these gaps by providing an 
ontological representation of glycan defects that complements 
and integrates with existing phenotype ontologies, and informs 
improved representation of glycans and related concepts in 
orthogonal efforts. The MGPO will support computational 
tools for disease diagnosis, disease gene candidate 
prioritization, and model system discovery.   
II. RESULTS  
A. Requirements Analysis and Curation  Activities 
MGPO development was largely driven by curation of 
glyco-phenotype data from the literature and datasets provided 
by collaborators such as the Undiagnosed Disease Program 
[8], and the Undiagnosed Disease Network. To date, we have 
manually curated glycol-phenotypes from 100 human 
diseases, 31 papers from human, and 11 papers from mouse 
related to abnormalities in glycobiology as showed in Table 1. 
For each glycophenotype captured, we indicated the source 
(e.g. PMID), the assay (e.g. MALDI-TOF), the subject (e.g. 
patient), the disease (e.g. OMIM), the evaluant (e.g. urine), the 
analyte (e.g. free oligosaccharides), the phenotype statement 
(e.g. accumulation of high mannose free oligosaccharides). 
 
TABLE I. Glycobiology and disease curation spreadsheet - 
example of a glycophenotype for Gaucher disease 
 
B. Development of initial MGPO prototype. 
With a rich set of curated data in hand, the next challenge is 
to synthesize this information to identify the key dimensions of 
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glycan phenotypes on which the ontology would be classified. 
We begin by listing each distinct glyco-phenotype curated 
from the sources above, and looked for patterns that would 
reveal important features for their categorization. Four essential 
dimensions reveal themselves through this exercise:   
1. Affected glycan characteristic. This dimension 
distinguishes phenotypes based on the general type of 
glycan feature or process affected: (e.g. glycan structure, 
occupancy, composition, levels, activity). 
2. Affected glycan type. This dimension distinguishes 
phenotypes based on the class of glycan exhibiting 
abnormal characteristics.   
3. Affected glycosylation target. This dimension 
distinguishes phenotypes based on the aglycone target 
affected by a defect. 
4. Affected locus of abnormality. This dimension 
distinguishes phenotypes based on the subcellular 
location of the defect  and/or the tissue or fluid where it 
was measured. 
The next step was applying these dimensions as 
classification axes to build a hierarchical model. Careful 
consideration was given to the order in which the 
dimensions should be applied to confer the optimal 
structure to the ontology. An initial straw man was 
generated for testing and eliciting expert feedback for 
iterative improvement, and is available at 
http://bit.ly/23kdoyj   
C. Evaluation and feedback provided to related databases 
and ontologies such as ChEBI and GO 
We next evaluated glycan-related coverage of orthogonal 
efforts including ChEBI, GO, HPO, and various glycan 
databases. Here we noted an underrepresentation of concepts 
needed to describe glyco-phenotypes like those we had 
curated form the literature. In GO, grouping categories are 
missing, for instance, glycan binding proteins (R-type lectin, 
L-type lectin, C-type lectin, P-type lectin, I-type lectin, 
galectin). Also, glycan-related synonyms are not present (e.g. 
“core 1” = T antigen).  
In ChEBI, labels are not always aligned with common 
domain use - for instance ChEBI’s use of ‘glycans' as 
synonym for 'carbohydrate'. There are key gaps in 
representation, for instance, no representation of N- and O-
glycans as groups, absence of many molecular species 
reported as diseases markers, absence of synonyms commonly 
used in glycobiology, etc. In HPO/MP, glyco-phenotypes are 
also underrepresented. For instance, a search for terms 
“oligosacchariduria” shows only sialidated and disaccharides 
excretion while more than fifty glycophenotypes were 
detected in the urine from ten different diseases [5]. In 
metabolomics databases, glycans with masses under 1,500 da 
are severely underrepresented with mostly only mono or di-
saccharides and their derivatives. For instance, a search of the 
term “glycan” in the ‘Metabolomics Workbench’ database [7] 
leads to only 6 molecules, while more than 30 N-glycan 
precursors can be identified in the Endoplasmic Reticulum [4].  
This contrasts with the abundance of chemical 
characteristics of glycans in glycobiologist databases such as 
UniCarbKB, GlycomeDB and Japan Consortium For 
Glycobiology and Glycotechnology Database (JCGGDB) [9]. 
Nevertheless, links between glycophenotypes and diseases are 
still lacking in these glycan databases. 
III. APPLICATIONS AND FUTURE DIRECTIONS 
The MGPO will be integrated with existing 
phenotype ontologies such as the Human Phenotype Ontology 
(HPO), and Mammalian Phenotype Ontology (MP), to support 
research and clinical application of ontology-driven methods. 
MGPO will serve as a bridge between existing glycan related 
databases and metabolomics, databases, between glycan 
databases and diseases databases. As part of the Monarch 
Initiative [6], the MGPO will be applied in semantic similarity 
approaches for the purposes of (1) disease diagnosis, (2) 
identification of patient cohorts for clinical studies, (3) 
discovery of model organisms to researching rare disease, and 
(4) identifying candidate genes underlying undiagnosed 
diseases. The MGPO will also be applied to annotate 
glycomics data from our partners in the Undiagnosed Disease 
Network, and support its use in semantic similarity and pattern 
matching analyses that can facilitate disease diagnosis and 
characterization.  
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